Abstract

Building cellular models of disease based on the approach of Cellular Systems Biology (CSB)™ has the potential to improve the process of creating drugs as part of the continuum from early drug discovery through drug development and clinical trials and diagnostics. This paper focuses on the application of CSB to early drug discovery. We discuss the integration of protein-protein interaction biosensors with other multiplexed, functional biomarkers as an example in using CSB to optimize the identification of quality lead series compounds.

Keywords: Cellular systems biology, cancer, cellular models of disease, fluorescent protein biosensors, protein-protein interactions, p53, tumor suppressor, high content screening